These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26332597)

  • 41. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical trials in children--between the expectations of scientific requirements, the assurance of proven treatment and ethical demands].
    Lehmann B; Mentzer D; Fischer T; Mallinckrodt-Pape K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):410-6. PubMed ID: 19266173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulatory aspects of Phase 3 endpoints for new inhaled antibiotics for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections.
    Montgomery AB; Abuan T; Yeager MA
    J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):198-203. PubMed ID: 22857271
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk/benefit evaluation of drugs: the role of the pharmaceutical industry in Germany.
    Schosser R
    Eur Surg Res; 2002; 34(1-2):203-7. PubMed ID: 11867924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Challenges for clinical trials in oncology within the scope of early benefit assessment of drugs].
    Lange S
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(6):417-30. PubMed ID: 26474646
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug development in oncology: a regulatory perspective.
    Augustus S
    Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.
    Carver KH; Elikan J; Lietzan E
    Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of early efficacy endpoints for proof-of-concept trials.
    Chen C; Sun L; Li CL
    J Biopharm Stat; 2013 Mar; 23(2):413-24. PubMed ID: 23437947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparative legal analysis of social media advertising of drugs in Germany and the United States.
    Buechner B
    Food Drug Law J; 2013; 68(3):259-79, i-ii. PubMed ID: 24640610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Federal approaches to the regulation of noncigarette tobacco products.
    Freiberg MJ
    Am J Prev Med; 2012 Nov; 43(5 Suppl 3):S249-54. PubMed ID: 23079224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
    Rogowski WH; Landauer M; John J
    Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.
    Meadows NA; Morrison A; Brindley DA; Schuh A; Barker RW
    Pharmacogenomics J; 2015 Feb; 15(1):6-12. PubMed ID: 25287070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharma on the hot seat.
    Huberfeld N
    J Health Law; 2007; 40(2):241-65. PubMed ID: 17849829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The costs of new drugs compared to current standard treatment].
    Ujeyl M; Schlegel C; Gundert-Remy U
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):461-7. PubMed ID: 24238023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
    Leong J; McAuslane N; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Orphan Drugs: Underrated Opportunities for The Developers in Europe].
    Tillet Y; Maillols-Perroy AC
    Therapie; 2015; 70(4):351-7. PubMed ID: 25997721
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA.
    Molitor M; Dintsios CM
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):145-157. PubMed ID: 32043904
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.